FDA approves talazoparib combination for specified metastatic prostate cancers — sources for revision 1
U.S. Food and Drug Administration
Source date: 2026-10-26.
Supporting location: Approved indication, TALAPRO-3, immature overall survival and safety warnings.
Source dates are distinct from Iliyn’s preparation date. Source statements do not independently prove underlying events. No full source articles or source photographs are reproduced.